艾美疫苗午前涨逾16% 个性化mRNA宫颈癌治疗疫苗即将申报临床

新浪港股
Aug 27
热点栏目 自选股 数据中心 行情中心 资金流向 模拟交易
客户端

  艾美疫苗(06660)盘中涨超17%,截至发稿,股价上涨15.79%,现报1.87港元,成交额194.42万港元。

  Moderna mRNA癌症疫苗III期临床取得里程碑式成功,引爆全球mRNA赛道行情。艾美mRNA癌症疫苗管线极为丰富,精准布局了与Moderna相同的mRNA黑色素瘤疫苗,同时还布局了mRNA宫颈癌疫苗(HPV治疗性mRNA疫苗)、mRN甲肝癌疫苗(肝癌治疗性mRNA疫苗)、mRNA肺癌疫苗(肺癌治疗性mRNA疫苗)等。其中,个性化mRNA宫颈癌治疗疫苗即将申报临床。

  据艾美疫苗副总裁张凡介绍,艾美布局癌症疫苗近十年,是国内最早布局mRNA癌症疫苗的企业。自2017年起,公司便深耕mRNA技术平台,是国内较早取得mRNA技术自主专利的疫苗企业,同时深耕mRNA癌症疫苗和mRNA预防疫苗两大赛道。艾美目前取得14个国内、国际mRNA疫苗的临床批件,是国内获得mRNA疫苗临床批件最多的公司。其中,mRNA带状疱疹疫苗,mRNA RSV疫苗已获批在中美两国开展临床试验。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10